BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 07-Nov-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.

BXPHARMA 24-Oct-2021

There will be no price limit on the trading of the shares of the Company today (24.10.2021) following its corporate declaration.

BXPHARMA 24-Oct-2021

The Board of Directors has recommended 35% cash dividend for the year ended on June 30, 2021. Date of AGM: 23.12.2021, Time: 10:30 AM, Venue: Digital Platform. Record Date: 22.11.2021. The Company has also reported Consolidated EPS of Tk. 11.49, Consolidated NAV per share of Tk. 83.01 and Consolidated NOCFPS of Tk. 13.50 for the year ended on June 30, 2021 as against Tk. 7.88, Tk. 80.12 and Tk. 13.67 respectively for the same period of the previous year.

BXPHARMA 12-Oct-2021

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 21, 2021 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.

BXPHARMA 03-Oct-2021

Referring to their earlier news disseminated by DSE on 24.01.2021, 05.09.2021 and 14.09.2021 regarding acquisition of a majority stake in Sanofi Bangladesh Limited, the Company has further informed that they have now completed its acquisition of the majority stake in Sanofi Bangladesh Limited. The final consideration, payable in cash (post the closing adjustments previously outlined), was approximately BDT 469.62 crore (Equivalent pound 39.35 million).

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): In the year ended 31 December 2020 (the last audited accounts prepared by Sanofi Bangladesh), Sanofi Bangladesh generated revenue of Taka 3.038 billion (approximately 25.8 million Pound), profit before tax of Taka 277.6 million (approximately 2.35 million Pound) and had gross assets of Taka 6.409 billion (approximately 54.4m Pound). A further announcement will be made in due course to confirm final completion of the Acquisition. (End)

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): Sanofi Bangladesh has over 800 employees and produces approximately 100 branded generic products, predominately for the local market. Sanofi Bangladesh has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. Sanofi also supplies its global brands of vaccines, insulins and chemotherapy drugs to Bangladesh through direct imports, which the Group will continue to distribute following the completion of the Acquisition. (Cont. 4)

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed in 2013 as Sanofi Bangladesh Limited. Sanofi Bangladesh's state-of-the-art manufacturing facilities, including a PICIS certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located near Beximco Pharma's manufacturing facility in Tongi. (Cont. 3)

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): while enabling the Company to consolidate its position as a leading pharmaceutical in Bangladesh by adding an established business with a reputation for high-quality products. Sanofi Bangladesh has been part Sanofi SA ("Sanofi"), a global biopharmaceutical company focused on human health. The operations in Bangladesh were established in 1958 as part of the British chemical company, May & Baker. (Cont. 2)

BXPHARMA 14-Sep-2021

Refer to the earlier news disseminated by DSE on 24 January 2021 and 05 September 2021, the Company has further informed that the company has now entered into the share purchase agreement to acquire the majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") (the "Acquisition"). The proposed earnings accretive Acquisition is in line with Beximco Pharma's strategy to expand its capabilities and product offering into new specialty therapy areas (Cont. 1)

Previous Next page